PROM1 and neoplasm: demonstrated that that insulin-like growth factor II mRNA-binding protein 3 (IGF2BP3) overexpression in Liver-CSCs upregulates CD133 and ABC transporters, enhancing tumor sphere formation and conferring resistance to sorafenib and doxorubicin (522).